TN2010000292A1 - 6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists - Google Patents

6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Info

Publication number: TN2010000292A1
Authority: TN; Tunisia
Prior art keywords: receptor antagonists; oxepine; dibenzo; mineralocorticoid receptor; nonsteroidal mineralocorticoid
Prior art date: 2007-12-19

Application number

TN2010000292A

Other languages

English (en)

Inventor

Konstantinos Gavaridanas

Parabhakar Kondaji Jadhav

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-19

Filing date

2010-06-18

Publication date

2011-11-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000292(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-06-18 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2011-11-11 Publication of TN2010000292A1 publication Critical patent/TN2010000292A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

TN2010000292A 2007-12-19 2010-06-18 6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists TN2010000292A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1477607P	2007-12-19	2007-12-19
PCT/US2008/085997 WO2009085584A1 (fr)	2007-12-19	2008-12-09	Antagonistes non steroïdaux du récepteur de minéralocorticoïdes dérivés de 6h-dibenz0 [b, e] oxépine

Publications (1)

Publication Number	Publication Date
TN2010000292A1 true TN2010000292A1 (en)	2011-11-11

Family

ID=40430143

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000292A TN2010000292A1 (en)	2007-12-19	2010-06-18	6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Country Status (33)

Country	Link
US (1)	US7994164B2 (fr)
EP (2)	EP2537845B1 (fr)
JP (1)	JP5562866B2 (fr)
KR (1)	KR101254382B1 (fr)
CN (1)	CN101903377B (fr)
AR (1)	AR069554A1 (fr)
AU (1)	AU2008343524B2 (fr)
BR (1)	BRPI0820805A2 (fr)
CA (1)	CA2710409C (fr)
CL (1)	CL2008003600A1 (fr)
CO (1)	CO6300953A2 (fr)
DK (1)	DK2235007T3 (fr)
DO (1)	DOP2010000185A (fr)
EA (1)	EA017668B1 (fr)
EC (2)	ECSP10010266A (fr)
ES (2)	ES2396605T3 (fr)
GT (1)	GT201000179A (fr)
HR (1)	HRP20120916T1 (fr)
IL (1)	IL206353A (fr)
MA (1)	MA31910B1 (fr)
MX (1)	MX2010006911A (fr)
MY (1)	MY150474A (fr)
NZ (1)	NZ586300A (fr)
PE (1)	PE20091057A1 (fr)
PL (1)	PL2235007T3 (fr)
PT (1)	PT2235007E (fr)
RS (1)	RS52594B (fr)
SI (1)	SI2235007T1 (fr)
TN (1)	TN2010000292A1 (fr)
TW (1)	TWI431010B (fr)
UA (1)	UA100131C2 (fr)
WO (1)	WO2009085584A1 (fr)
ZA (1)	ZA201004257B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2188274A4 (fr)	2007-08-03	2011-05-25	Boehringer Ingelheim Int	Inhibiteurs de polymerase virale
US8476257B2 (en)	2007-12-19	2013-07-02	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
KR101312179B1 (ko) *	2009-03-12	2013-09-26	일라이 릴리 앤드 캄파니	미네랄로코르티코이드 수용체 길항제 및 사용 방법
JP6148175B2 (ja)	2010-05-10	2017-06-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	網膜中および／または網膜下における液体貯留の処置のための方法および組成物
EP2582365B1 (fr)	2010-06-16	2019-03-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions pour stimuler la réépithélialisation durant la cicatrisation d'une blessure
CN102060670A (zh) *	2011-01-04	2011-05-18	常州大学	一种2-溴-6-氟苯甲醇的制备方法
CN105164134B (zh)	2013-05-02	2017-09-22	辉瑞大药厂	作为pde10抑制剂的咪唑并‑三嗪衍生物
AR099416A1 (es)	2014-02-28	2016-07-20	Lilly Co Eli	Terapia combinada para la hipertensión resistente
CA2953655C (fr)	2014-06-30	2020-05-12	Astrazeneca Ab	Amides de benzoxazinone comme modulateurs du recepteur des mineralcorticoides
EP3221310A1 (fr) *	2014-11-21	2017-09-27	Eli Lilly And Company	Composés 1,2-benzothiazoles destinés au traitement d'affections rénales
EP3362095B1 (fr)	2015-10-13	2020-11-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes et préparations pharmaceutiques pour le traitement de la neovascularisation choroidienne
US20190262363A1 (en)	2016-07-26	2019-08-29	INSERM (Institut National de la Santé et de la Recherche Médicale	Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
TN2019000063A1 (en) *	2016-09-24	2020-07-15	Kbp Biosciences Co Ltd	Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
WO2021180818A1 (fr)	2020-03-11	2021-09-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés permettant de déterminer si un sujet a ou risque d'avoir une choriorétinopathie séreuse centrale
US20240366632A1 (en)	2021-08-31	2024-11-07	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4072756A (en) *	1973-05-17	1978-02-07	Sandoz Ltd.	Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) *	1980-02-14	1985-09-23	Fagersta Ab	Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) *	1986-09-10	1988-04-07	Canon Kk	Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
US4999363A (en) *	1988-06-09	1991-03-12	Kyowa Hakko Kogyo Co., Ltd.	Tricyclic compounds
GB8914061D0 (en) *	1989-06-19	1989-08-09	Wellcome Found	Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) *	1991-12-27	1995-01-03	Kyowa Hakko Kogyo	Tricyclic compounds
CO4980885A1 (es)	1997-12-29	2000-11-27	Ortho Mcneil Pharm Inc	Compuestos de trifenilpropanamida utiles en el tratamiento de inflamaciones y metodos para preparar dicho compuesto
US7056911B1 (en)	1999-01-26	2006-06-06	Dana-Farber Cancer Institute	Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
SI1448566T1 (sl) *	2001-11-21	2006-08-31	Millennium Pharm Inc	Antagonisti kemokinskega receptorja in postopki njihove uporabe
TW200400816A (en) *	2002-06-26	2004-01-16	Lilly Co Eli	Tricyclic steroid hormone nuclear receptor modulators
WO2005066153A1 (fr) *	2003-12-19	2005-07-21	Eli Lilly And Company	Modulateurs du recepteur nucleaire d'hormone steroide tricyclique
CN1918151A (zh)	2003-12-19	2007-02-21	伊莱利利公司	三环甾类激素核受体调节剂
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
RU2007107177A (ru)	2004-07-28	2008-09-10	Айрм Ллк (Bm)	Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
CN102731499B (zh)	2004-11-10	2016-01-13	因塞特控股公司	内酰胺化合物及其作为药物的应用
WO2008053300A1 (fr)	2006-10-31	2008-05-08	Pfizer Products Inc.	Composés de pyrazoline en tant qu'antagonistes des récepteurs minéralocorticoïdes
US20100120736A1 (en)	2007-03-29	2010-05-13	N.V. Organon	Mineralocorticoid Receptor Antagonists
GB0725102D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
PE20091339A1 (es)	2007-12-21	2009-09-26	Glaxo Group Ltd	Derivados de oxadiazol con actividad sobre receptores s1p1
JP2011510073A (ja)	2008-01-25	2011-03-31	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１アゴニストとして作用するジヒドロ−１Ｈ−ピロロ［１，２−ａ］インドール−１−イルカルボン酸誘導体
KR101312179B1 (ko)	2009-03-12	2013-09-26	일라이 릴리 앤드 캄파니	미네랄로코르티코이드 수용체 길항제 및 사용 방법

2008
- 2008-12-02 PE PE2008002008A patent/PE20091057A1/es not_active Application Discontinuation
- 2008-12-02 TW TW097146779A patent/TWI431010B/zh not_active IP Right Cessation
- 2008-12-03 AR ARP080105263A patent/AR069554A1/es unknown
- 2008-12-03 CL CL2008003600A patent/CL2008003600A1/es unknown
- 2008-12-09 RS RS20120541A patent/RS52594B/sr unknown
- 2008-12-09 MY MYPI20102867 patent/MY150474A/en unknown
- 2008-12-09 CN CN200880121527.2A patent/CN101903377B/zh not_active Expired - Fee Related
- 2008-12-09 US US12/330,539 patent/US7994164B2/en not_active Expired - Fee Related
- 2008-12-09 ES ES08866835T patent/ES2396605T3/es active Active
- 2008-12-09 BR BRPI0820805-0A patent/BRPI0820805A2/pt not_active IP Right Cessation
- 2008-12-09 NZ NZ586300A patent/NZ586300A/en not_active IP Right Cessation
- 2008-12-09 HR HRP20120916AT patent/HRP20120916T1/hr unknown
- 2008-12-09 ES ES12185389.9T patent/ES2459318T3/es active Active
- 2008-12-09 AU AU2008343524A patent/AU2008343524B2/en not_active Ceased
- 2008-12-09 SI SI200830852T patent/SI2235007T1/sl unknown
- 2008-12-09 UA UAA201007627A patent/UA100131C2/uk unknown
- 2008-12-09 DK DK08866835.5T patent/DK2235007T3/da active
- 2008-12-09 JP JP2010539618A patent/JP5562866B2/ja not_active Expired - Fee Related
- 2008-12-09 KR KR1020107013601A patent/KR101254382B1/ko not_active Expired - Fee Related
- 2008-12-09 CA CA2710409A patent/CA2710409C/fr not_active Expired - Fee Related
- 2008-12-09 EP EP12185389.9A patent/EP2537845B1/fr active Active
- 2008-12-09 PL PL08866835T patent/PL2235007T3/pl unknown
- 2008-12-09 MX MX2010006911A patent/MX2010006911A/es active IP Right Grant
- 2008-12-09 EA EA201070762A patent/EA017668B1/ru not_active IP Right Cessation
- 2008-12-09 EP EP08866835A patent/EP2235007B1/fr active Active
- 2008-12-09 WO PCT/US2008/085997 patent/WO2009085584A1/fr not_active Ceased
- 2008-12-09 PT PT88668355T patent/PT2235007E/pt unknown
2010
- 2010-06-14 MA MA32909A patent/MA31910B1/fr unknown
- 2010-06-14 IL IL206353A patent/IL206353A/en not_active IP Right Cessation
- 2010-06-15 ZA ZA2010/04257A patent/ZA201004257B/en unknown
- 2010-06-16 CO CO10072532A patent/CO6300953A2/es not_active Application Discontinuation
- 2010-06-17 GT GT201000179A patent/GT201000179A/es unknown
- 2010-06-17 EC EC2010010266A patent/ECSP10010266A/es unknown
- 2010-06-17 DO DO2010000185A patent/DOP2010000185A/es unknown
- 2010-06-18 TN TN2010000292A patent/TN2010000292A1/fr unknown
2012
- 2012-07-17 EC ECSP12012048 patent/ECSP12012048A/es unknown

Also Published As

Publication number	Publication date
HK1144284A1 (en)	2011-02-11
KR20100082866A (ko)	2010-07-20
MX2010006911A (es)	2010-10-05
TWI431010B (zh)	2014-03-21
AU2008343524A1 (en)	2009-07-09
SI2235007T1 (sl)	2013-01-31
MA31910B1 (fr)	2010-12-01
IL206353A0 (en)	2010-12-30
RS52594B (sr)	2013-04-30
PT2235007E (pt)	2013-01-22
ECSP12012048A (es)	2012-08-31
PE20091057A1 (es)	2009-07-20
KR101254382B1 (ko)	2013-04-15
CL2008003600A1 (es)	2010-02-19
PL2235007T3 (pl)	2013-03-29
UA100131C2 (uk)	2012-11-26
EA201070762A1 (ru)	2010-12-30
EP2537845A1 (fr)	2012-12-26
ES2459318T3 (es)	2014-05-09
CA2710409A1 (fr)	2009-07-09
ECSP10010266A (es)	2010-07-30
ZA201004257B (en)	2011-11-30
JP2011507868A (ja)	2011-03-10
CO6300953A2 (es)	2011-07-21
EP2537845B1 (fr)	2014-03-19
AU2008343524B2 (en)	2012-03-08
CN101903377B (zh)	2014-07-09
NZ586300A (en)	2012-06-29
DOP2010000185A (es)	2010-09-15
US20090163472A1 (en)	2009-06-25
TW200930721A (en)	2009-07-16
EA017668B1 (ru)	2013-02-28
IL206353A (en)	2014-06-30
EP2235007B1 (fr)	2012-10-31
HRP20120916T1 (hr)	2012-12-31
GT201000179A (es)	2012-04-16
AR069554A1 (es)	2010-02-03
JP5562866B2 (ja)	2014-07-30
US7994164B2 (en)	2011-08-09
EP2235007A1 (fr)	2010-10-06
CN101903377A (zh)	2010-12-01
DK2235007T3 (da)	2012-12-17
WO2009085584A1 (fr)	2009-07-09
BRPI0820805A2 (pt)	2015-06-16
CA2710409C (fr)	2012-11-06
ES2396605T3 (es)	2013-02-22
MY150474A (en)	2014-01-30

Publication	Publication Date	Title
TN2010000292A1 (en)	2011-11-11	6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
MY157525A (en)	2016-06-15	Inhibitors of the renal outer medullary potassium channel
WO2008040649A3 (fr)	2008-05-29	Dérivés de pyrazine-2-carboxamide
WO2007133653A3 (fr)	2008-01-24	Procédés de traitement de troubles sanguins
WO2007092879A3 (fr)	2008-03-27	Inhibiteurs de kinase thiatriazaacénaphthylène-6-carbonirile substitués
EA200970583A1 (ru)	2009-12-30	Способ получения пиперазиниловых и диазепаниловых производных бензамида
WO2007109783A3 (fr)	2008-08-21	Inhibiteurs de pyrimidine kinase substituee
MX2009009416A (es)	2009-09-11	Derivados de bencimidazol y sus metodos de uso.
EA201190207A1 (ru)	2012-04-30	Соединения для лечения метаболических расстройств
MX2010002899A (es)	2010-04-09	Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
WO2007121154A3 (fr)	2008-07-17	Inhibiteurs de benzothiazole substitués
UA104867C2 (uk)	2014-03-25	Похідні феноксихроманкарбонової кислоти, заміщені в 6-ому положенні
SE0800742L (sv)	2009-10-03	Vikttäcke
MX2007011847A (es)	2008-03-11	Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
MX2011009506A (es)	2011-09-28	Antagonista del receptor mineralcorticoide y metodos de uso.
MX2013004739A (es)	2013-07-02	Derivados heterociclicos de diazenodiolato.
WO2009009122A3 (fr)	2009-06-25	Dérivés de l'urée et de diamines associées, leurs procédés de fabrication, et leurs utilisations
EA201001828A1 (ru)	2011-04-29	Способ синтеза производных 3,6-дигидро-1,3,5-триазина
WO2009037586A3 (fr)	2010-01-14	Utilisation d'agonistes peptidiques du récepteur de la vasopressine
MY163348A (en)	2017-09-15	Primary amine diazeniumdiolate heterocyclic derivatives
WO2007084591A3 (fr)	2007-11-15	Formes solides d’acide carboxylique (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-méthoxybenzoyl]-1,2,3,5-tétrahydro-spiro[4h-1-benzazépine-4,1'-[2]cyclopentène]-3'
WO2006120472A3 (fr)	2007-05-10	Nouveaux composes beta-steroides
EA201001872A1 (ru)	2011-04-29	Новые способы получения производных циклопропиламида
WO2009145358A3 (fr)	2010-05-06	Médicament pour la prophylaxie ou pour le traitement de l'hypertension
SE0701694L (sv)	2009-01-13	Nya bronkdilaterande a,b-omättade amider